Description
Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Nefopam Hydrochloride Injection (Lyophilized) |
| Generic Name | Nefopam Hydrochloride |
| CAS Number | 13669?70?0 (Nefopam) 1mg.com+11en.wikipedia.org+11ryvispharma.com+11pubchem.ncbi.nlm.nih.gov |
| Chemical Formula | C??H??NO·HCl |
| Molecular Weight | ?289.8?g/mol |
| Dosage Form | Sterile lyophilized powder for reconstitution |
| Strength | 20?mg per 2?mL vial |
| Pack Size | 10 vials per box |
| Approval No. | China NMPA H37021048 |
| Product Code | 86904083000868 |
| Manufacturer | Shandong Faming Pharmaceutical Group Co., Ltd. |
| Barcode | 6935030530637 |
| Storage | Store at 2–25?°C; protect from light and moisture; reconstitute with sterile water |
| Intended Use | Laboratory research use only |
Mechanism of Action
Nefopam is a centrally acting analgesic that inhibits reuptake of serotonin, norepinephrine, and dopamine, and modulates glutamatergic pathways and sodium?calcium channels, providing non-opioid pain relief without respiratory depression .
Research Applications & Pharmacology
Acute and Post-Operative Pain Models: Effective for moderate to severe pain in preclinical models .
Chronic/Cancer Pain Studies: Used both in acute and chronic pain protocols .
Multimodal Analgesia: Frequently combined with opioids or NSAIDs to reduce opioid dosage and adverse effects .
Pharmacokinetics: Half-life ~3–8?hr; metabolized hepatically; excreted via urine (~79%) and feces (~13%) .
Safety Profile & Handling
Adverse Effects: May include nausea, sweating, dizziness, urinary retention, tachycardia, hallucinations, seizures (rare) .
Contraindications: History of epilepsy, myocardial infarction, narrow-angle glaucoma, MAO inhibitors, hypersensitivity .
Handling Prep: Reconstitute under aseptic conditions, inspect for clarity, do not mix with incompatible agents.
Storage/Preparation: Store vials sealed and protected; discard reconstituted solution per institutional protocols.


Reviews
There are no reviews yet.